chrisvoncsefalvay/vaers-outcomes huggingface dataset:
swollen lymph nodes under injection site; swollen lymph nodes under injection site; Booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 39 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 30Nov2021 16:00 (Batch/Lot number: unknown) at the age of 38 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LIPITOR. Past drug history included: Ceftin, reaction(s): "known allergies: Ceftin", notes: known allergies: Ceftin. Vaccination history included: Bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot unknown: True, prev dose lot unknown reason: Misplaced/discarded, prev dose administration date: 12Apr2021, prev dose administration time: 02:15 PM, prev dose number: 2, prev dose vaccine location: Right arm), administration date: 12Apr2021, when the patient was 38 years old, for COVID-19 immunization; Bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, prev dose lot unknown: True, prev dose lot unknown reason: Misplaced/discarded , prev dose administration date: 22Mar2021, prev dose administration time: 02:30 AM, prev dose number: 1, prev dose vaccine location: Left arm), administration date: 22Mar2021, when the patient was 38 years old, for COVID-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 30Nov2021 16:00, outcome "unknown", described as "Booster"; VACCINATION SITE REACTION (non-serious), LYMPHADENOPATHY (non-serious) all with onset 01Dec2021 22:00, outcome "not recovered" and all described as "swollen lymph nodes under injection site". Therapeutic measures were not taken as a result of vaccination site reaction, lymphadenopathy.  Additional information: The patient did not take any other vaccination in four weeks. The patient did not had COVID prior vaccination or tested COVID post vaccination.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Numbness noted left lower lip area noted when woke up the morning after COVID19 Vaccine.  The numbness subsided before noon same day
Left thigh induration and erythema 4 1/2cm X 6 1/2cm. Advised to use ice and Motrin.
malaise, exhaustion, aching, sore, chills, fever, headache, nausea, migraine
Employee received flu shot 7 days ago and broke out with fine red rash on trunk that itches a great deal 2 days later.  No other symptoms noted.  Rash spread to upper extremities.
This is a spontaneous report from a contactable consumer (patient himself). A male patient of an unspecified age received bnt162b2 (PFIZER BIONTECH COVID-19 VACCINE, formulation: solution for injection, unknown lot number), dose 2 via an unspecified route of administration on an unspecified date in 2021 as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of bnt162b2 (PFIZER BIONTECH COVID-19 VACCINE, formulation: solution for injection) on an unknown date as single dose for covid-19 immunisation. Patient received the two doses of the Pfizer´s COVID-19 vaccine, he was not sure but believes that it could have been two months ago on an unknown date in 2021. He was an immunocompromised patient and presented no antibodies after receiving the second dose of the Pfizer's COVID-19 vaccine. When he received the second dose of the vaccine he had mild flu like symptoms. He also wanted to know if a low level of antibodies could indicate that he requires a third "booster" dose. He was advised to get revaccinated by his physician. Patient underwent lab test which included antibody test on an unknown date in 2021 and which showed no antibodies. The outcome of the events was unknown.  The lot number for the vaccine bnt162b2 was not provided and has been requested.
Patient reports that a posterior headache that radiated down into his cervical spine, lasting several hours each day. Not present at night. Getting better with time.
This case was reported by a pharmacist and described the occurrence of red rash injection site in a subject of unspecified age and gender who was vaccinated with FLUARIX (GlaxoSmithKline). In October 2008, the subject received a dose of FLUARIX (.5 ml, unknown). In October 2008, at an unspecified time after vaccination with FLUARIX, the subject experienced red rash injection site and pharmaceutical product complaint. The pharmacist received a call from a nurse at a nursing home facility that reported that 80 out of 100 subjects developed a "grapefruit size bright red" rash at the injection site. At the time of reporting the outcome of the events were unspecified. For the other 79 linked subjects please see cases: A0756483A - A0756490A, A0756492A - A0756562A. The CRC provided lot number AFLUA3208A to QA regarding this product complaint, while the report received in CMG Safety stated AFLUA3508A. With a possibility of a coding mistake to batch AFLUA320AA and on the basis that there are 80 cases out of 100, it was decided to ask for a Quality investigation (including cold chain) of all three batches (correct numbers: AFLUA350BA, AFLUA320BA and AFLUA320AA). On 16 January 2009, QA results were received for batches reviewed of (AFLUA320AA and AFLUA320BA): AFLUACA320, AFLUA320A, and AFLUA320B. The report indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batches AFLUA320AA and AFLUA320BA. On 26 March 2009, QA results were received for batches reviewed (AFLUA350BA): AFLUCA350 and AFLUA350B. The report indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batch AFLUA350BA.
Fatigue , SOB (shortness of breath), Dyspnea on exertion, Generalized weakness, Respiratory distress, COVID-19 vaccine administered  Asthma exacerbation Possible COVID-91 allergic reaction   Nebs, inhalers,  IV and oral steroids, oxygen   Symptoms ongoing
I am covered in a severe rash that itches burns and tingles. First RX was a 4mg prednisone pack that did not help from an urgent care facility. I then went to Dr who gave me RX and the next day it was worse again so the current RX is described earlier. It is not getting any worse but I am struggling to not itch. I can not wear clothes for long periods of time and it is quite debilitating  Clothes
I had the first shot of the Moderna Covid vaccine on 1-13-2021. I had the usual swelling and soreness at the injection site. That went away by that Saturday/Sunday.  That following Wed. 1-20-21, the soreness and redness came back. The redness was a little larger than the size of a quarter  but had started to go away again in a couple of days On  1-27-21, I noticed  the injection site was tender, swollen, and red again and this time the redness was larger than before, about the size of a small saucer. It is now a couple of days later from the last flare up and the swelling is pretty much gone again along with tenderness. You can still clearly see the redness but it is much lighter in color than before.
Headache; Malaise; flu like symptoms; This case was reported by a pharmacist via call center representative and described the occurrence of headache in a 60-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 17th May 2019, the patient received the 1st dose of Shingrix. On 18th May 2019, 1 days after receiving Shingrix, the patient experienced headache, malaise and influenza-like symptoms. On 18th May 2019, the outcome of the headache, malaise and influenza-like symptoms were recovered/resolved.   It was unknown if the reporter considered the headache, malaise and influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The pharmacist reported he experienced slight flu like symptoms, such as malaise and headache. The healthcare professional noted that the headache and malaise completely resolved by the afternoon of the day they began. The healthcare professional could not provide lot number and expiration date. This case has been linked with US2019092210, reported by same reporter.
Pt recvd Hep B vax & PPD tests; the PPD showed a positive rxn; p/CXR pts MD stated the pos test was due to vax w/recomb; MD stated that this rxn was well documented;
Varicella Information has been received from a physician and a school nurse concerning an 10 year old female who June 1996 was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). It was also noted that the patient was vaccinated with a dose of measles virus vaccine live (Ender-Edmonston) (+) mumps virus vaccine live (Jeryl-Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) on 15-SEP-1996 and 01-JUN-1999. A school nurse reported to the physician that between 24-MAR-2005 and 09-MAY-2005 the child developed a mild case of break through varicella with less than 50 lesion. Unspecified medical attention was sought. The outcome was recovered. A product quality complain was not involved. No additional information is expected.
Resident received 1 dose of Pfizer COVID vaccine on 1/12/21 and 2 doses of Moderna COVID vaccine 4/1/21 and 4/29/21. No adverse events.
Muscle/joint pain; Muscle/joint pain; 101.6 temp; chills; sicky feeling, stayed in bed 36 hours; This is a spontaneous report from a contactable consumer (patient). A 71-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL9263; expiry date: unknown) via an unspecified route of administration in the left arm, on 22Jan2021, at 15:45, at a single dose, for Covid-19 immunization. The patient's medical history was not reported. Concomitant medications included hydrochlorothiazide, colecalciferol (VIT D3), cetirizine hydrochloride (ZYRTEC), and azelastine hcl. The patient previously took codeine and experienced allergies (itchy skin). The patient was not diagnosed with COVID prior vaccination. The patient did not receive other vaccines within four weeks prior to COVID vaccination. Place of vaccination was reported as "other". On 23Jan2021, at 12:00 AM, the patient experienced muscle/joint pain, 101.6 temperature (temp), chills, and sicky feeling (stayed in bed for 36 hours). The events were considered non-serious. The patient did not receive treatment for the events. Outcome of the events was recovered. The patient has not been tested for COVID-19 since vaccination.
Patient states her headache started yesterday afternoon (7/19/23) after receiving the HPV vaccine. Patient states she woke up this morning (7/20/23) with a fever up to 103F, chills, headache, and nausea.   Patient's mother states patient experienced the same symptoms after receiving the first and second dose of HPV vaccine. Patient's mother states she was hospitalized two years ago for her symptoms, but was never given a diagnosis.
Exactly two weeks later, I was walking and felt a cramp in my left butt check. I worked in the yard the next day. The following Monday, I was walking and the cramp happened again and I almost didn't make it back to my car. It went from my hip all the way down to my toes. It was horrific. I tried a week of rest and taking Ibuprofen, but there was no improvement. I went to see a Chiropractor and it didn't help, so I went to my Orthopedist. I was prescribed a steroid and more time off, but that didn't help. Next we did an MRI and it revealed some bulging discs. I was then prescribed Gabapentin, 400mg, and it knocked me out. I even had a hard time waking up. I was referred to another doctor and he ended up lowering the dosage. I started physical therapy and that helped a lot. I went to see another doctor and by that time, I was feeling better, so he told me to continue my physical therapy. I'm not completely recovered, but I'm functional.
Pt. states he experienced HA sore (R) arm from shoulder to hand, malaise, increased anxiety causing chest tightness & diarrhea. Sx started in afternoon throughout noc. At time of visit today at approx 0930 he was WNL of his usual (R) arm without swelling or redness.
Reaction that is reddish to pinkish in color; Little itchy; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Reaction that is reddish to pinkish in color) and PRURITUS (Little itchy) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 05J20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (Reaction that is reddish to pinkish in color) and PRURITUS (Little itchy). At the time of the report, ERYTHEMA (Reaction that is reddish to pinkish in color) and PRURITUS (Little itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment information provided
Recipient received pfizer vaccine at 12:22. Vaccinator reports recipient had no voiced concerns or s/s of anxiety at time of vaccination. Recipient talkative in exit area with no outward signs of distress. Sitting in chair when he lost consciousness at 12:28. Guided to floor by this reporter and and 1 additional clinician. As recipient was guided to floor rigidity was noted and he started to experience seizure like activity, jerking movements, foaming at the mouth. He was turned on his side and material placed under head. Jerking movements lasted for 45 seconds after which time the patient continued to have eyes closed, breathing sonorous, unlabored, small amount of blood on lips.
This spontaneous report was received from a registered nurse referring to a 12 month old patient. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On 29-SEP-2017, the patient was vaccinated with an expired dose of M-M-R II lot # L035674 and expiration date on 17-SEP-2017, subcutaneously (dose was not reported) for prophylaxis, which was reconstituted with sterile diluent (DILUENT MRK). No adverse effects were present. There were no temperature excursions and no product quality complaints reported.
Patient was registered to get a Janssen Covid Booster vaccine and a Fluarix vaccine was administered
Patient given Covid shot was sitting out in waiting room chair and passed out then came to minutes after Covid vaccine. Patient very diaphoretic. VS - 86 - 20 - 120/78 Sat 96% BS - 134 Patient did not eat breakfast this am. Patient given cool rags and fan at this time.
102 degree fever. Very bad headache. Loss of eye contact and poor social function prior to receiving round of first vaccines. 2 older brothers have history of heightened sensitivity to many preservatives and ingredients, but we were assured that vaccines would not be harmful. Both of our older sons are now autistic, and were not born so. Patient was a happy baby. After receiving the vaccines, he was fussy, and since has stopped sleeping normally, and has had more fevers and rashes and lack of eye contact. He stopped trying to roll over or move on his own for about a month post vaccination. This is a huge concern as he was hitting milestones wonderfully prior. We did not seek immediate help. We decided to wait and decided to see if he would feel better after a few days. Then he was so sick. Seemingly with one cold virus after another, and then with a horrible cough and ear infection, which we saught treatment for at Health Center in December, No injury report was filed. I felt like no one would listen to my concern. I'm not anti vaccines. I am just concerned about my baby. With so many cases of aubism and other disorders in our genes, I am worried that I we may be too sensitive for these shots. I really would like someone to respond via Email or telephone. Thank you for your time.
Severe abdominal pain and cramping starting 12 hours after vaccine.   Was severe for 12 hours and then improved but has had continued cramping and discomfort for 10 days
This spontaneous case was reported by a patient and describes the occurrence of NECK PAIN (Neck pain), CHILLS (Chills) and ARTHRALGIA (Shoulder pain) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis. Concurrent medical conditions included Rheumatoid arthritis (MODERATE TO SEVERE). In April 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In October 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced NECK PAIN (Neck pain), CHILLS (Chills) and ARTHRALGIA (Shoulder pain). At the time of the report, NECK PAIN (Neck pain), CHILLS (Chills) and ARTHRALGIA (Shoulder pain) outcome was unknown. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medication was not provided. Unknown Date in 2022 patient received booster vaccine. Action taken with Humira was unknown, dechallenge was not applicable for events Neck pain, Chills and Shoulder pain. The reporter's causality for co-suspect Humira for the events Neck pain, Chills and Shoulder pain was not provided. No treatment information was provided by the reporter.
Miscarriage at 22 weeks. No fetal heartbeat after first Covid shot. Had to give birth to still born baby.
Some nausea 2 days after; Soreness at injection site; This is a spontaneous report from a contactable consumer, the patient. A 38-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the arm left on 31Mar2021 at 12:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Concomitant medications included escitalopram oxalate (LEXAPRO)  and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) for unknown indication, from an unspecified date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 14:00 hours the patient experienced soreness at injection site.  On 02Apr2021, (2 days after vaccine) the patient experienced some nausea. No therapeutic measures were taken for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events soreness at injection site, some nausea were recovering.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
2nd shot past 42 days; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (2nd shot past 42 days) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (2nd shot past 42 days). On 17-May-2021, PRODUCT DOSE OMISSION ISSUE (2nd shot past 42 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.   Reporter did not allow further contact
pt recvd Engerix-B & w/in a day exp labyrinthitis, nausea, & vomiting; treated w/antiemetics; pt still has dizziness & difficulty reading;
Painful swollen arm, rash on back that itches and resembles measles according to patient.
This spontaneous report was received from a physician and from a support services director via company representatives and refers to a patient of an unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 15-FEB-2016, the patient was vaccinated with a dose of an improperly stored GARDASIL 9 (strength: 0.5 ml) lot # L014198 and expiration date: 05-SEP-2017 (dose, anatomical location and route of administration were not reported). No adverse effects were reported. The dose of the vaccine was exposed to different temperature excursions (date unspecified): lasting for 144, and 360 hours, with the lowest recorded temperature of 33, and 34 degrees Fahrenheit (0.55, and 1.11 degrees Celsius) respectively. The vaccine was stored in a refrigerator. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Blood clot in left arm. My arm swollen in Jan, Feb, Mar, Apr, May, and in June my arm swelling didn?t subside and when I contacted my PCP she said get to the ER you have a blood clot.  ER did a sonogram of arm and discovered a huge blood clot. I have been taking Eliquis since and hopefully will get off of it in Dec2021. My first injection was in Jan 2021 & then Feb 2021. I received my booster yesterday and have a rash at injection site on right arm.
Almost immediate pain at injection site. Over the next couple of days there was a lot of swelling in my arm; a large, red circle around the injection site and a lot of pain.  The swelling, redness and pain lasted over 2 weeks. My arm is currently back to normal.
This spontaneous report was received from the patient's mother, referring to her son, a 5 year old male patient with asthma but no drug reactions or allergies. On 30-JUL-2015, the patient was vaccinated with a dose of VARIVAX (Merck) (lot number and expiration date unspecified, dose and route of administration were not reported, in the leg), a dose of M-M-R II (lot number and expiration date unspecified, dose and route of administration were not reported, in the leg), a dose of DTaP, a dose of IPV (unspecified) and a dose of OPV-MERIEUX. Concomitant therapies included SYMBICORT, NASACORT and SINGULAIR. On 30-JUL-2015, after the vaccines were received (reported as immediately), the patient developed unspecified red, local rashes at the injection sites and red rings that surrounded each injection site. Also, "growing pain" like pains limited to only the injection sites on each leg were the vaccines were given, that accompanied an unspecified low grade fever. Whenever the patient did experience the "growing pain" like pains, the red ring that surrounded the injection sites developed again. The patient visited his primary care physician, but she was unable to make a diagnosis. On an unknown date, the patient was admitted to hospital A (unspecified admission and discharge date) and, therefore on 25-SEP-2015, transferred to hospital B and admitted on the same date. Multiple unspecified blood tests were completed during the hospitalization time, showing inconclusive result, with only "a few", unspecified "inflammation markers" were elevated. The patient was treated with unspecified antibiotics, possibly including ZITHROMAX, since the unspecified physicians at the hospital thought the patient had cellulitis. On 26-SEP-2015, the patient was discharged from hospital B. The outcome and causality cellulitis was unknown. Additional information has been requested.
VACCINE WAS GIVEN TO PATIENT OUTSIDE OF TEMPERATURE WINDOW. NO SIGNS OR SYMPTOMS WERE REPORTED OR OBSERVED